Cargando…

Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study

INTRODUCTION: The organization of health care for breast cancer (BC) constitutes a public health challenge to ensure quality of care, while also controlling expenditure. Few studies have assessed the global care pathway of early BC patients, including a description of direct medical costs and their...

Descripción completa

Detalles Bibliográficos
Autores principales: Héquet, Delphine, Huchon, Cyrille, Soilly, Anne-Laure, Asselain, Bernard, Berseneff, Helene, Trichot, Caroline, Combes, Aline, Alves, Karine, Nguyen, Thuy, Rouzier, Roman, Baffert, Sandrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619952/
https://www.ncbi.nlm.nih.gov/pubmed/31291250
http://dx.doi.org/10.1371/journal.pone.0210917
_version_ 1783433973168340992
author Héquet, Delphine
Huchon, Cyrille
Soilly, Anne-Laure
Asselain, Bernard
Berseneff, Helene
Trichot, Caroline
Combes, Aline
Alves, Karine
Nguyen, Thuy
Rouzier, Roman
Baffert, Sandrine
author_facet Héquet, Delphine
Huchon, Cyrille
Soilly, Anne-Laure
Asselain, Bernard
Berseneff, Helene
Trichot, Caroline
Combes, Aline
Alves, Karine
Nguyen, Thuy
Rouzier, Roman
Baffert, Sandrine
author_sort Héquet, Delphine
collection PubMed
description INTRODUCTION: The organization of health care for breast cancer (BC) constitutes a public health challenge to ensure quality of care, while also controlling expenditure. Few studies have assessed the global care pathway of early BC patients, including a description of direct medical costs and their determinants. The aims of this multicenter prospective study were to describe care pathways of BC patients in a geographic territory and to calculate the global direct costs of early stage BC during the first year following diagnosis. METHODS: OPTISOINS01 was a multicenter, prospective, observational study including early BC patients from diagnosis to one-year follow-up. Direct medical costs (in-hospital and out-of-hospital costs, supportive care costs) and direct non-medical costs (transportation and sick leave costs) were calculated by using a cost-of-illness analysis based on a bottom-up approach. Resources consumed were recorded in situ for each patient, using a prospective direct observation method. RESULTS: Data from 604 patients were analyzed. Median direct medical costs of 1 year of management after diagnosis in operable BC patients were €12,250. Factors independently associated with higher direct medical costs were: diagnosis on the basis of clinical signs, invasive cancer, lymph node involvement and conventional hospitalization for surgery. Median sick leave costs were €8,841 per patient and per year. Chemotherapy was an independent determinant of sick leave costs (€3,687/patient/year without chemotherapy versus €10,706 with chemotherapy). Forty percent (n = 242) of patients declared additional personal expenditure of €614/patient/year. No drivers of these costs were identified. CONCLUSION: Initial stage of disease and the treatments administered were the main drivers of direct medical costs. Direct non-medical costs essentially consisted of sick leave costs, accounting for one-half of direct medical costs for working patients. Out-of-pocket expenditure had a limited impact on the household.
format Online
Article
Text
id pubmed-6619952
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-66199522019-07-25 Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study Héquet, Delphine Huchon, Cyrille Soilly, Anne-Laure Asselain, Bernard Berseneff, Helene Trichot, Caroline Combes, Aline Alves, Karine Nguyen, Thuy Rouzier, Roman Baffert, Sandrine PLoS One Research Article INTRODUCTION: The organization of health care for breast cancer (BC) constitutes a public health challenge to ensure quality of care, while also controlling expenditure. Few studies have assessed the global care pathway of early BC patients, including a description of direct medical costs and their determinants. The aims of this multicenter prospective study were to describe care pathways of BC patients in a geographic territory and to calculate the global direct costs of early stage BC during the first year following diagnosis. METHODS: OPTISOINS01 was a multicenter, prospective, observational study including early BC patients from diagnosis to one-year follow-up. Direct medical costs (in-hospital and out-of-hospital costs, supportive care costs) and direct non-medical costs (transportation and sick leave costs) were calculated by using a cost-of-illness analysis based on a bottom-up approach. Resources consumed were recorded in situ for each patient, using a prospective direct observation method. RESULTS: Data from 604 patients were analyzed. Median direct medical costs of 1 year of management after diagnosis in operable BC patients were €12,250. Factors independently associated with higher direct medical costs were: diagnosis on the basis of clinical signs, invasive cancer, lymph node involvement and conventional hospitalization for surgery. Median sick leave costs were €8,841 per patient and per year. Chemotherapy was an independent determinant of sick leave costs (€3,687/patient/year without chemotherapy versus €10,706 with chemotherapy). Forty percent (n = 242) of patients declared additional personal expenditure of €614/patient/year. No drivers of these costs were identified. CONCLUSION: Initial stage of disease and the treatments administered were the main drivers of direct medical costs. Direct non-medical costs essentially consisted of sick leave costs, accounting for one-half of direct medical costs for working patients. Out-of-pocket expenditure had a limited impact on the household. Public Library of Science 2019-07-10 /pmc/articles/PMC6619952/ /pubmed/31291250 http://dx.doi.org/10.1371/journal.pone.0210917 Text en © 2019 Héquet et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Héquet, Delphine
Huchon, Cyrille
Soilly, Anne-Laure
Asselain, Bernard
Berseneff, Helene
Trichot, Caroline
Combes, Aline
Alves, Karine
Nguyen, Thuy
Rouzier, Roman
Baffert, Sandrine
Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study
title Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study
title_full Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study
title_fullStr Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study
title_full_unstemmed Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study
title_short Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study
title_sort direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: results of a french multicenter prospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619952/
https://www.ncbi.nlm.nih.gov/pubmed/31291250
http://dx.doi.org/10.1371/journal.pone.0210917
work_keys_str_mv AT hequetdelphine directmedicalandnonmedicalcostsofaoneyearcarepathwayforearlyoperablebreastcancerresultsofafrenchmulticenterprospectivestudy
AT huchoncyrille directmedicalandnonmedicalcostsofaoneyearcarepathwayforearlyoperablebreastcancerresultsofafrenchmulticenterprospectivestudy
AT soillyannelaure directmedicalandnonmedicalcostsofaoneyearcarepathwayforearlyoperablebreastcancerresultsofafrenchmulticenterprospectivestudy
AT asselainbernard directmedicalandnonmedicalcostsofaoneyearcarepathwayforearlyoperablebreastcancerresultsofafrenchmulticenterprospectivestudy
AT berseneffhelene directmedicalandnonmedicalcostsofaoneyearcarepathwayforearlyoperablebreastcancerresultsofafrenchmulticenterprospectivestudy
AT trichotcaroline directmedicalandnonmedicalcostsofaoneyearcarepathwayforearlyoperablebreastcancerresultsofafrenchmulticenterprospectivestudy
AT combesaline directmedicalandnonmedicalcostsofaoneyearcarepathwayforearlyoperablebreastcancerresultsofafrenchmulticenterprospectivestudy
AT alveskarine directmedicalandnonmedicalcostsofaoneyearcarepathwayforearlyoperablebreastcancerresultsofafrenchmulticenterprospectivestudy
AT nguyenthuy directmedicalandnonmedicalcostsofaoneyearcarepathwayforearlyoperablebreastcancerresultsofafrenchmulticenterprospectivestudy
AT rouzierroman directmedicalandnonmedicalcostsofaoneyearcarepathwayforearlyoperablebreastcancerresultsofafrenchmulticenterprospectivestudy
AT baffertsandrine directmedicalandnonmedicalcostsofaoneyearcarepathwayforearlyoperablebreastcancerresultsofafrenchmulticenterprospectivestudy